Ad/AAV Hybrid Vectors Construction
Recently, studies have shown that inverted repeat sequences inserted into the genome of the first-generation adenovirus (Ad) vector mediate precise genomic rearrangements, resulting in the lack of all viral genes in the vector genome that are efficiently packaged into the functional Ad capsid. As a leader in this field, Creative Biolabs has been able to provide high-quality services for the construction of Ad/adeno-associated virus (AAV) hybrid vectors by virtue of our extensive experience in viral vectors, and to better benefit the field of gene therapy.
Ad/AAV Hybrid Vector for Gene Therapy
Successful gene therapy depends on the "bell and whistle" of transgene delivery vectors. Ideally, these vectors should not only transfer a large target gene to the target cell, but also permanently express the gene. It is becoming more and more obvious that none of the vectors currently being developed can meet the needs of human gene therapy. With the development of high titer virus production methods, AAV vectors are more and more widely used in gene therapy. It is a protein shell that surrounds and protects a small single-stranded DNA genome of about 4.8 kb. AAV belongs to the parvovirus family and mainly depends on the co-infection of adenovirus for replication. In current viral vectors, Ad vectors have the ability to transfer a large DNA fragment (~150 kb) into cells, while AAV vectors can integrate the gene into mammalian cell genome for long-term gene expression. Using these two viral vectors to develop a hybrid transmission system containing their advantages has become the research goal of many research groups, which greatly promotes the development of gene therapy vectors.
Figure 1. AAV vector strategy of delivery.1
The Rationale for Ad/AAV Hybrid Vectors
To overcome the limitations of individual vector systems, Ad/AAV hybrid vectors were developed. These systems strategically combine the high delivery efficiency and large cargo capacity of adenovirus with the long-term expression and favorable safety profile of AAV.
| Feature | Adenovirus (Ad) | AAV | Ad/AAV Hybrid |
|---|---|---|---|
| Packaging Capacity | Up to 36 kb | ~4.7 kb | Large payload with AAV regulatory elements |
| Transduction Efficiency | Very High | Moderate | Very High |
| Duration of Expression | Short-term | Long-term | Long-term with rapid onset |
| Immunogenicity | Moderate to High | Low | Optimized/Reduced |
| Genome Persistence | Episomal | Episomal/Integration (rare) | Enhanced stability |
| Suitability for Complex Constructs | Excellent | Limited | Excellent |
Ad/AAV hybrid vectors therefore represent a next-generation gene delivery strategy, enabling researchers to achieve efficient, durable, and flexible therapeutic gene expression.
Why Hybrid AD-AAV Vectors? The Limitation of Conventional Systems
| Challenge in Gene Delivery | Limitations of Single Vector Systems | Our Ad/AAV Hybrid Solutions |
|---|---|---|
| Payload capacity | AAV limited (~4.7 kb) | Adenovirus backbone enables larger cargo delivery |
| Expression duration | Adenovirus = transient expression | AAV elements enable long-term expression |
| Genome integration | Adenovirus does not integrate | AAV components support stable persistence/integration |
| Transduction efficiency | AAV lower in some cell types | Adenovirus ensures high transduction efficiency |
| In vivo performance | Trade-off between efficiency vs stability | Hybrid system combines both advantages |
Ad/AAV Hybrid Vectors Development at Creative Biolabs
Gene transfer vectors are widely used in preclinical research of animal models of diseases, and are the research tools to realize gene transfer in vivo and in vitro. We are committed to providing customizable vectors for researchers with low cost and high quality in a short time to promote the development of gene therapy. The engineering of hybrid vectors makes it possible to combine the advantages of different viral vectors. As an expert in the field of viral vectors, we constructed a chimeric Ad/AAV vector containing a first-generation Ad vector and a reporter gene flanked by the inverted terminal repeat (ITR) sequences of AAV to achieve chromosomal integration. In transduced cell lines, randomly integrated reporter genes showed stable long-term expression. In addition, we combine the package signal from the helper-dependent adenoviral (HDAd) with the integrated signal from the AAV. Through Cre/LoxP mediated recombination (which is an integral experimental tool for mammalian genetics and cell biology), the hybrid vectors can be packaged into virus particles similar to Ads, which greatly reduces the infection rate of HDAd vectors. This hybrid has about 14 kB of transgenic ability and can adapt to the most common genes.
Technical Architecture of AD-AAV Hybrid Vectors
How It Works
Our hybrid vectors are built on a gutless adenovirus backbone (lacking all viral coding sequences) that carries:
- Transgene expression cassette (up to 8 kb)
- AAV inverted terminal repeats (ITRs) flanking the transgene
- AAV Rep78/68 gene (provided in trans or cis, depending on design)
Two principal configurations:
Type I: Hybrid Ad/AAV Vector (Helper-dependent)
- Backbone: HDAd with all Ad genes deleted
- Cargo: Therapeutic gene + AAV ITRs
- AAV Rep supplied: In trans via a separate plasmid or helper virus
- Result: High-titer vector (>10^12 vp/mL) with minimal immunogenicity
Type II: Ad-AAV Chimeric Capsid
- Backbone: Adenovirus capsid pseudotyped with AAV serotype fibers
- Cargo: Full AAV genome (ITRs + Rep/Cap + transgene) packaged into Ad capsid
- Result: Retargeted tropism + AAV-like entry pathway
Both formats are available – our scientists will recommend the optimal architecture based on your target tissue, required expression duration, and immunogenicity tolerance.
Key Advantages of Our AD-AAV Hybrid Platform
1. Unmatched Cargo Capacity
Deliver genes up to 8 kb – accommodate full-length dystrophin, Factor VIII, ABCA4, or large promoter elements. Dual-transgene cassettes also fit seamlessly.
2. Reduced Immunogenicity
Our helper-dependent Ad backbone contains no viral coding sequences, eliminating de novo synthesis of Ad antigens. Result: Minimal CD8+ T cell response against transduced cells, enabling repeat administration – a major hurdle for standard Ad vectors.
3. Site-Specific Integration (Optional)
Unlike wild-type AAV, our hybrid system incorporating AAV Rep targets the well-characterized AAVS1 safe harbor locus. This reduces insertional mutagenesis risk and ensures stable transgene expression without silencing.
4. Flexible Pseudotyping
Choose from over 12 AAV serotypes or engineered capsids for:
- Neuronal tropism (AAV9, AAVrh10)
- Muscle transduction (AAV1, AAV6, AAV8)
- Retinal targeting (AAV2, AAV5, AAV8)
- Liver specificity (AAV8, AAV9)
Comprehensive Service Workflow
Step 1: Design Consultation
- Submit your gene sequence (or we synthesize codon-optimized version)
- Define target cell type / tissue, desired expression duration, and budget
- Our vectorologists recommend optimal hybrid architecture (Type I or Type II), promoter, enhancer, and serotype
Step 2: Vector Cloning & Verification
- Ad backbone: Helper-dependent Ad5 (E1/E3 deleted, all viral ORFs removed)
- Cargo cloning: Transgene + AAV ITRs inserted into shuttle plasmid
- AAV Rep provision: Co-transfection with Rep-expressing helper plasmid (or Cre/loxP system for HDAd)
- Verification: Restriction mapping, Sanger/NGS sequencing, and PCR for ITR integrity
Step 3: Virus Production & Amplification
- Transfection: HEK293 cells (or PerC6 for higher yield) with Ad backbone + helper plasmids
- Harvest: Cells lysed 48–72h post-transfection, crude lysate collected
- Amplification: Sequential infection of suspension HEK293 cells in bioreactors (2–3 rounds)
- Optimization: MOI, cell density, and harvest time tuned for maximum titer
Step 4: Purification & Concentration
- Clarification: Centrifugation + 0.45 μm filtration
- Purification: Two-step CsCl density gradient ultracentrifugation or iodixanol gradient for GMP
- Concentration: Ultrafiltration to 10^12–10^13 vp/mL
- Buffer exchange: PBS, 10% glycerol, or customized formulation (e.g., lactated Ringer's for in vivo)
Step 5: Quality Control & Release
| Test | Method | Specification |
|---|---|---|
| Titer (physical) | qPCR/ddPCR (ITR region) | ≥1×10^12 vp/mL |
| Titer (infectious) | TCID50 on HEK293 | ≥1×10^10 IU/mL |
| Purity | SDS-PAGE + silver stain | ≥95% (no contaminating proteins) |
| Endotoxin | LAL assay | ≤1 EU/mL (preclinical) |
| Replication-competent Ad | PCR for E1 region | Not detected |
| Sterility | 14-day culture | Negative |
| Mycoplasma | qPCR | Negative |
Step 6: Functional Validation (Optional)
- In vitro: Transduction of target cell line; qRT-PCR/ELISA/Western for transgene expression; integration PCR (AAVS1 junction)
- In vivo: Pilot study in mice (IV, IM, or retro-orbital) – biodistribution (qPCR for vector genomes in tissues), expression (immunohistochemistry), and safety (AST/ALT, cytokines)
Step 7: Delivery & Technical Support
- Ship on dry ice with stability data (6 months at -80°C)
- One-year free storage at our facility
- Unlimited post-delivery troubleshooting via video call or email
Case Study: In Vivo Validation of Hybrid Vector for Large Gene Delivery
Objective: Compare AD-AAV hybrid vs. AAV alone for delivery of a 6.5 kb therapeutic gene (secreted alkaline phosphatase, SEAP) in mice.
Methods:
- Group 1: AAV2/8 (ITRs only) – cannot package >4.7 kb → no functional vector produced.
- Group 2: Standard Ad5 (E1/E3 deleted) – 6.5 kb SEAP expression cassette.
- Group 3: AD-AAV hybrid (Type I, helper-dependent Ad5 with AAV2 ITRs and trans Rep) – 6.5 kb SEAP.
- Dose: 5×10^10 vp/mouse, IV tail vein.
- Readouts: Serum SEAP activity (days 1–56); liver histology (H&E); anti-Ad5 antibodies (ELISA).
Results:
| Parameter | Ad5 only | AD-AAV Hybrid |
|---|---|---|
| Peak SEAP (Day 3) | 120 μg/mL | 115 μg/mL |
| SEAP at Day 56 | <1 μg/mL | 22 μg/mL |
| ALT (Day 7, U/L) | 850 (severe hepatitis) | 95 (normal range 30–100) |
| Anti-Ad5 IgG (Day 56) | 1:12,800 | 1:800 |
| AAVS1 integration (PCR) | Not detected | Positive in 12% of hepatocytes |
Conclusion: The AD-AAV hybrid achieved long-term expression (22% of peak at 8 weeks) with minimal hepatotoxicity and lower immunogenicity compared to standard Ad5. Site-specific integration was confirmed.
Features of Our Ad/AAV Hybrid Vector Construction Service
- Providing customized services for each step of the Ad/AAV hybrid vectors construction process
- Providing short-hairpin RNA (shRNA) screening and validation services for cells
- Good quality control
Frequently Asked Questions (FAQ)
Q: Can the AD-AAV hybrid vector integrate into the host genome without AAV Rep?
A: No. Without Rep78/68, the AAV ITRs alone do not support integration – the vector remains episomal (like standard AAV). For site-specific integration, we supply Rep in trans. For transient expression (e.g., vaccine or CRISPR delivery), we omit Rep to avoid off-target integration risk.
Q: What is the maximum transgene size you can package?
A: Our validated upper limit is 8 kb (including promoter, transgene, polyA, and ITRs). For larger constructs (8–10 kb), we offer a dual-hybrid strategy – two complementary vectors that reconstitute via Cre/loxP or intein-mediated splicing.
Q: Do you offer serotype screening for tropism optimization?
A: Yes. For a flat fee, we produce a small panel (5 serotypes: e.g., AAV1, 2, 5, 8, 9) at 10^11 vp each. We transduce your target cells and provide a tropism report with transduction efficiency (flow cytometry or qPCR) before scaling up your chosen serotype.
Q: What factors should be considered when selecting Ad/AAV hybrid vectors over other large-gene delivery strategies?
A: Selecting the most appropriate gene delivery system depends on several scientific and therapeutic factors. Ad/AAV hybrid vectors are particularly advantageous when the therapeutic gene exceeds the packaging capacity of AAV alone and when both rapid onset and sustained expression are required. Unlike dual AAV systems, which rely on intracellular recombination of two separate vectors, Ad/AAV hybrid vectors can deliver the complete genetic payload in a single system, resulting in more consistent and efficient gene expression. These hybrid vectors are also beneficial for delivering complex constructs such as CRISPR/Cas genome-editing systems, multi-gene cassettes, or regulatory networks. Additionally, they provide a favorable safety profile with a very low risk of insertional mutagenesis compared to integrating vectors like lentivirus.
Q: What information should clients provide to initiate an Ad/AAV hybrid vector construction project?
A: To ensure an efficient and streamlined project initiation, clients are encouraged to provide several key pieces of information. These include the therapeutic gene sequence and its size, which are essential for determining vector feasibility and design. Details about the desired expression profile—such as promoter preferences, expression duration, and target tissue or cell type—help guide the selection of regulatory elements and optimization strategies. Information regarding any preferred vector components, such as reporter genes, inducible systems, or tissue-specific promoters, is also valuable.
Start Your Project Today
By partnering with Creative Biolabs, you gain access to cutting-edge hybrid vector technologies and a team of experienced scientists dedicated to your success. We are ready to support your journey from concept to preclinical validation. Contact us today to discuss your project requirements or request a customized quote, and discover how our Ad/AAV hybrid vector construction service can accelerate your gene therapy research and development.
Reference
- Moldavskii D, Gilazieva Z, Fattakhova A, et al. AAV-based gene therapy: opportunities, risks, and scale-up strategies. International Journal of Molecular Sciences, 2025, 26(17): 8282. https://doi.org/10.3390/ijms26178282 Distributed under Open Access license CC BY 4.0, without modification.
